Land: Sør-Afrika
Språk: engelsk
Kilde: South African Health Products Regulatory Authority (SAHPRA)
Schering
QUINAGLUTE DURA-TABS SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): QUINAGLUTE DURA-TABS Tablets COMPOSITION Each tablet contains quinidine gluconate 324 mg in a tablet matrix specially designed for the prolonged (8 or 12 hour interval) release of the medicine in the gastro-intestinal tract. Quinidine gluconate contains 62,3% of the anhydrous quinidine alkaloid, whereas quinidine sulphate contains 82,86%. In prescribing Quinaglute Dura-Tabs, this factor should be considered. PHARMACOLOGICAL CLASSIFICATION A. 6.2 Cardiac depressants. PHARMACOLOGICAL ACTION The antiarrhythmic activity of quinidine consists of two basic actions: (a) prolongation of effective refractory period of the atrial or ventricular muscle which leads to termination of arrhythmia; (b) decrease in excitability of ectopic foci of the heart. The action is not limited to these two properties on the heart. In addition, quinidine (c) blocks vagal innervation and (d) facilitates conduction in the atrioventricular junction. In the treatment of cardiac arrhythmia, quinidine is administered in a dose that will exert actions (a) and (b) with a minimal effect on (c) and (d). INDICATIONS For the prevention of premature atrial, nodal or ventricular contractions. For maintenance of normal sinus rhythm following conversion by other techniques of atrial, nodal or ventricular tachycardia, atrial flutter and fibrillation (paroxysmal or chronic). CONTRA-INDICATIONS Aberrant impulses and abnormal rhythms due to escape mechanisms should not be treated with quinidine. Partial A-V or complete heart block, or intraventricular conduction defects, especially those exhibiting a marked grade of QRS widening. Renal disease resulting in significant azotemia, or those developing cardiotoxic effects such as conduction defects, ventricular premat Les hele dokumentet